Drug Profile
Research programme: filariasis and tuberculosis therapies - Pfizer
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Class Organic boron compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Filarial elephantiasis; Onchocerciasis; Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Filarial elephantiasis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Onchocerciasis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis in USA